【問題】Swindells s et al n engl j med 2020 382 1112 23 ?推薦回答
關於「Swindells s et al n engl j med 2020 382 1112 23」標籤,搜尋引擎有相關的訊息討論:
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 ...。
et al. March 19, 2020. N Engl J Med 2020; 382:1112-1123. DOI: 10.1056/NEJMoa1904398. Article; Figures/Media. Metrics. 23 References; 84 Citing Articles ...: tw | tw。
Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART ...。
2021年7月12日 · Object name is fimmu ... Whitney et al. explored the use of N-803 [IL-15 superagonist that has ... New Engl J Med (2020) 382(12):1112–23.。
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF ... - NCBI。
2020年12月18日 · Doravirine (DOR) is a nonnucleoside reverse-transcriptase inhibitor. In the phase 3 DRIVE-AHEAD trial in ... N Engl J Med 2020; 382:1112–23.: tw | tw。
An Overview of Human Immunodeficiency Virus-1 Antiretroviral Drugs。
2021年3月17日 · Because the main characteristic of HIV-1 is the reverse ... DNA Cell Biol 2004;23:191–192. ... N Engl J Med 2020;382:1112–1123.。
[PDF] Guidelines for the Use of Antiretroviral Agents in Adults and ...。
2019年12月18日 · 16. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J. Med.: 。
Systems and Clinical Pharmacology of COVID-19 Therapeutic ...。
2020年11月25日 · First, the antiviral strategy is intended to lower the risk of disease progression and severity, which may lead to death. Second, if the ...。
Bibliography - Course - National HIV Curriculum。
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505. PubMed Abstract ...。
[PDF] Curriculum Vitae - Harvard University。
Reviewer for JAMA, JAMA Pediatrics, British Medical Journal, PLoS One, AIDS, ... Kimmel GL, Williams PL, Kimmel CA, Claggett TW, Tudor N. Response-surface ...。
Publications | ResearchMatch。
Below is a list of publications that have been made possible thanks to ... JMIR formative research (2020) ... The New England journal of medicine (2020).。
圖片全部顯示
常見Swindells s et al n engl j med 2020 382 1112 23問答
延伸文章資訊The ATLAS ACS 2–TIMI 51 Trial and the Burden of Missing Data: (Anti-Xa Therapy to Lower Cardiovas...
... (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial ... Three patients in stratum...
In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients with a recen...
These percentages differ greatly from the ATLAS ACS‐2 TIMI 51 trial at large (24% unstable angina...
ATLAS ACS 2-TIMI 51 was a phase III, multicenter, randomized, double-blind, placebo-controlled cl...
The phase II ATLAS ACS–TIMI 46 trial noted that in patients with recent acute coronary syndrome (...
Design · Multicenter, double-blind, parallel group, randomized, placebo-controlled trial · N=15,3...
Objectives and methods:: ATLAS ACS 2-TIMI 51 was a double-blind, placebo-controlled clinical tria...
The ATLAS ACS 2–TIMI 51 Trial and the Burden of Missing Data: (Anti-Xa Therapy to Lower Cardiovas...
... (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial ... Three patients in stratum...
In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients with a recen...
These percentages differ greatly from the ATLAS ACS‐2 TIMI 51 trial at large (24% unstable angina...
ATLAS ACS 2-TIMI 51 was a phase III, multicenter, randomized, double-blind, placebo-controlled cl...
The phase II ATLAS ACS–TIMI 46 trial noted that in patients with recent acute coronary syndrome (...
Design · Multicenter, double-blind, parallel group, randomized, placebo-controlled trial · N=15,3...
Objectives and methods:: ATLAS ACS 2-TIMI 51 was a double-blind, placebo-controlled clinical tria...